Mammoth Bio CEO on Bayer Pact to Make Crispr Therapies

The video discusses Mammoth Biosciences' collaboration with Bayer to expand gene therapy using novel CRISPR systems, focusing initially on liver diseases. It highlights the potential of CRISPR proteins for in vivo applications and addresses ethical concerns in gene editing. The pandemic's role in accelerating CRISPR-based diagnostics is explored, along with the importance of transparency in scientific endeavors, drawing lessons from the Elizabeth Holmes case.

What are the main applications of the novel CRISPR proteins being developed at Mammoth?

Why is the focus on liver-based diseases for the initial applications of the CRISPR technology?

What ethical considerations does Mammoth focus on regarding gene editing technology?

How has the pandemic influenced the development of CRISPR-based diagnostic applications?

In what ways does Mammoth aim to be transparent about its CRISPR technology?